Yahoo · Sep 15, 2026
GSK Inks $750M Deal to Add Experimental Blood Cancer Therapy
GSK's $750M Chimagen deal adds a trispecific TCE to its multiple myeloma portfolio, targeting two tumor antigens simultaneously.
PG
NASDAQ · PGEN
Precigen, Inc.
Healthcare · Biotechnology
$7.00
Up+$0.44 (+6.21%)
Updated Sep 16, 2026, 9:17 PM
SID Score
6.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.09B
- P/E ratio
- -2.51
- Dividend yield
- 0.00%
- 52-week range
- $2.99 – $7.72
- Volume
- 2.78M
- Avg. volume
- 4.88M
Price performance
PGEN price history
1M range · 20 trading sessions · Daily adjusted prices
PGEN closed at $7.00 after 20 trading sessions, up 3.70% for the selected period.
- Last close
- $7.00
- Period change
- +3.70%
- Period low
- $6.68
- Period high
- $7.44
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $6.81 | $7.015 | $6.76 | $7.00 | 2.78M |
| Sep 14, 2026 | $6.86 | $7.11 | $6.83 | $6.85 | 2.83M |
| Sep 11, 2026 | $6.77 | $6.92 | $6.76 | $6.85 | 2.06M |
| Sep 10, 2026 | $6.70 | $6.73 | $6.54 | $6.68 | 2.84M |
| Sep 9, 2026 | $6.87 | $6.885 | $6.675 | $6.80 | 3.14M |
| Sep 8, 2026 | $6.89 | $7.02 | $6.72 | $6.87 | 2.77M |
| Sep 4, 2026 | $7.12 | $7.27 | $7.08 | $7.10 | 2.19M |
| Sep 3, 2026 | $7.00 | $7.14 | $6.98 | $7.14 | 2.19M |
| Sep 2, 2026 | $6.91 | $7.14 | $6.815 | $7.01 | 2.64M |
| Sep 1, 2026 | $6.81 | $7.00 | $6.80 | $6.86 | 2.81M |
| Aug 31, 2026 | $6.934 | $7.00 | $6.6016 | $6.93 | 4.14M |
| Aug 28, 2026 | $7.11 | $7.19 | $6.92 | $6.95 | 2.7M |
| Aug 27, 2026 | $7.435 | $7.46 | $7.14 | $7.19 | 4.98M |
| Aug 26, 2026 | $7.66 | $7.715 | $7.28 | $7.42 | 7.41M |
| Aug 25, 2026 | $7.29 | $7.55 | $7.23 | $7.28 | 5.84M |
| Aug 24, 2026 | $7.15 | $7.205 | $6.93 | $7.17 | 3.35M |
| Aug 21, 2026 | $7.50 | $7.50 | $7.10 | $7.20 | 4.41M |
| Aug 20, 2026 | $7.06 | $7.49 | $6.975 | $7.44 | 7.84M |
| Aug 19, 2026 | $6.97 | $7.21 | $6.80 | $7.16 | 8.15M |
| Aug 18, 2026 | $6.42 | $6.79 | $6.34 | $6.75 | 4.36M |
Latest PGEN news
The latest Smart Investors Daily articles mentioning PGEN.
Stock researchCompany · Overview
PGEN research
Overview
Company profile and research snapshot.
Company profile
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 5, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 3, 2026 | HC Wainwright & Co. | Buy | — |
| May 28, 2026 | HC Wainwright & Co. | Buy | — |
| May 14, 2026 | Citizens | Market Outperform | — |
| May 14, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
Generated Sep 16, 2026, 7:10 PM
Why Is PGEN Up Today?
Precigen shares gained 4.69% today, likely driven by positive momentum in the broader biotech sector and renewed investor interest in the company's pipeline developments. While today's headlines don't directly reference PGEN-specific news, the stock's movement suggests market optimism around clinical developments in its therapeutic areas.
Bottom line: PGEN's 4.69% gain appears to reflect positive sector momentum rather than company-specific catalysts, suggesting investors should monitor upcoming clinical updates and pipeline news for fundamental support. While the broader biotech landscape shows promise, investors should watch for PGEN's own clinical readouts and partnership announcements to validate whether today's gains have staying power.
Yahoo · Sep 15, 2026
Definium Reports Second Phase III Success in Anxiety Disorder Program
DFTX scores a second phase III GAD win as DT120 ODT delivers significant anxiety improvements, paving the way for FDA talks and a planned 2027 regulatory filing.
Yahoo · Sep 14, 2026
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC
GSK's Jideytro delivers strong first-line NSCLC results, with high response rates and durable disease control supporting a planned FDA filing.
Yahoo · Sep 11, 2026
AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
ABBV's atogepant delivers positive LUNA data in menstrual migraine, potentially expanding its migraine franchise and addressing an unmet need.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
